Stock Analiz

Neuraxis, INC NRXS

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2023 · data as of November 13, 2026

$5.42Market cap $77M
Open the interactive analysis →

Neuraxis, INC (NRXS) is a healthcare company listed in the US with a market value of about $77M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$12M, a net margin of -185.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -192%.

About Neuraxis, INC

Neuraxis, INC is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2023. Revenue went from $3M in 2022 to $4M in 2025, growth of about 10.0% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 353% over three years (dilution for shareholders). It spends 14% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.8
P/B21.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-8.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)32.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-324.5%
ROIC (5-yr avg.)-192.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$7M$4M$3M$2M$3M
Net income-$12M-$8M-$8M-$15M-$5M
Free cash flow-$6M-$6M-$6M-$7M-$2M
EPS (diluted)$-1.06$-0.95$-1.22$-4.50$-2.77
Net margin-185.2%-218.6%-306.8%-594.6%-178.1%
ROIC—-162.1%-222.5%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Neuraxis, INC pay a dividend?

Not currently.

Is Neuraxis, INC a good stock to buy?

We do not give buy or sell advice. Neuraxis, INC scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.